Permanent Hair Loss After Taxotere?
Let Our lawyers Help You
If you took Taxotere and experienced Perminent Hair loss after chemo therapy you may qualify for financial compensation.
Plaintiffs who filed a Taxotere lawsuit found to their dismay that the chemotherapy drug manufactured by Sanofi-Aventis might cause permanent hair loss. Used to treat several cancer types including breast, lung, and stomach, docetaxel is a highly toxic medicine whose side effects include alopecia, anemia, diarrhea, and weight loss. The pharmaceutical company, however, never warned the patients that in some instances baldness is not temporary.
If you or anyone in your family suffered from permanent alopecia after treatment with this medication, you might qualify for a large monetary compensation. Contact us right now: our lawyers will help you by providing free legal advice.
What is Taxotere?
Taxotere (docetaxel) is a drug of the “taxane” class used to treat many cancer types including gastric, breast, lung and prostate cancer. Originally manufactured by Sanofi-Aventis, this chemotherapy agent was approved by the U.S. Food and Drug Administration (FDA) in 1996. It is an anti-mitotic agent that acts by disrupting cellular division. Since tumor cells replicate at a much higher speed than normal ones, this medicine can stop them in their tracks while they spread through the body (metastasis).
It is usually administered intravenously over the course of a hour-long infusion cycle that is then repeated every 3-4 weeks. This chemotherapy agent is generally used in combination with other drugs such as doxorubicin, cyclophosphamide, fluorouracil, capecitabine, and cisplatin to fight off cancer and improve the patient’s chances of survival. While it was a branded medication, Taxotere was one of the most sold medicines worldwide, with over $1.2 billion sales from the US market alone. Before its patent expired in 2010 and the market was flooded with generic competition, the average cost of an 18-weeks treatment in Europe was about $7,500.
Cancer types for which Docetaxel is approved
Non-small cell lung cancer (NSCLC) | Breast cancer | Prostate cancer | Gastric cancer | Head and neck cancer
Med Lawsuit Group
Reviewed by Mary Vister on
“Truly The Best Team of Lawyers”
Meds Lawsuit Group, made it simple to file and easy to peruse for the medical damages Xarelto caused on my family.Rating: 5.0 ★★★★★
Schmidt National Law Group
San Diego CA, 92117
For years Sanofi-Aventis kept reassuring patients that the drug was safe and effective, even though it knew a terrible truth. The pharmaceutical company knew the results of the GEICAM 9805 clinical trial back in 2005, a study that revealed that 9.2 percent of patients who used the medication suffered from irreversible alopecia.
Our Lawyers understand baldness is a serious adverse reaction which may negatively affect our clients quality of life and body image. Its effects may hamper social functioning, self-esteem, and sexuality, leading to significant distress, anxiety, and depression. The Big Pharma purposely decided to withheld crucial information which prevented our clients them from choosing another chemotherapeutic agent for their cancer therapies.
Taxotere side effects
Taxotere side effects are experienced by up to 90 percent of the patients treated, and the drug’s toxicity must be closely monitored since it may even reach potentially lethal levels. In 2014, the FDA also found that some formulations of this medication contained significant quantities of ethanol and caused several cases of alcohol intoxication. Patients treated with this antiblastic agent should be warned before driving vehicles or operating machinery. This taxane has been classified as “Pregnancy Category: D”, meaning that there is positive evidence of fetal risk, especially if administered during the first trimester. Pregnant women who took it to treat their breast cancer later gave birth to babies with congenital malformations such as gastric stenosis and cerebral birth defects.
The most frequent adverse reactions of docetaxel are:
Neutropenia | Alopecia (hair loss) | Anemia |Thrombocytopenia | Nausea | Infection | Fever |Stomatitis |Esophagitis | Weight loss | Severe diarrhea | Leukemia | Heart failure |Neurosensory disturbances |Fluid retention | Nail discoloration
Taxotere Multidistrict Litigation
In October 2016, 33 hair loss lawsuits were been filed in 16 federal courts across the country. Taxotere attorneys thus asked a panel of judges to centralize all claims in a single U.S. District Court to speed up the proceedings and preserve the resources of the parties and courts by coordinating the discovery phase.
On July 22, 2016, a Motion for Transfer has already been filed with the U.S. Judicial Panel on Multidistrict Litigation (JPML). On October 4, the Panel consolidated the cases in the products liability litigation MDL no. 2740 in the Eastern District of Louisiana, overseen by Chief Judge Kurt D. Engelhardt after being reassigned from Honorable Judge Lance M. Africk. To date, on January 2017, at least 700 victims decided to step forward and tell their stories by filing a legal dispute, and the litigation is expected to grow even further within the next few months.
Docetaxel vs. Paclitaxel
Sanofi-Aventis widely advertised Taxotere as a safer and more effective medicine compared to its competitor Taxol (paclitaxel), an already established chemotherapy agent. Paclitaxel, however, was significantly less dangerous and could be used at lower doses, causing a reduced number of adverse reactions and a substantially lower toxicity.
An extensive study published in the journal Cancer Treatment Reviews compared the two taxanes in a real-world environment and found that the newer drug manufactured by Sanofi-aventis was neither safer nor more beneficial than Taxol. The only advantage of docetaxel over its older counterpart was that the treatment plan for Taxotere is once every three weeks instead of weekly, although the new taxane’s cost is much higher.
In April 2009, the FDA issued a warning letter to the pharmaceutical company because it presented “unsubstantiated superiority claims” over its competitor, releasing to the public false or misleading information that overstated the efficacy of docetaxel.
Ami Dodson alopecia lawsuit
One of the first permanent hair loss litigations filed against the manufacturer of Taxotere was Ami Dodson’s one. According to court documents presented in the U.S. District Court for the Northern District of California, the woman was diagnosed with breast cancer on March 3, 2010. After she had undergone breast surgery (mastectomy), Dodson had to choose her chemotherapy regimen, but neither she nor her doctor knew of the risk for long-lasting alopecia. Even long after her treatment was over, the woman’s hair never grew back, leaving her with a lifelong disfigurement. The plaintiff now seeks just compensation for all the damage she had to endure, as well as the emotional challenges and struggles she faced. In her lawsuit, Dodson claims that the company only gave a vague warning about the risk of baldness, but they never said that this side effect could be irreversible.
Kimberly Free v. Sanofi-Aventis, et al.
On April 2016, plaintiff Kimberly Free filed another dispute against Sanofi in the U.S. District Court for the Northern District of Texas. The woman was treated with docetaxel from October 2012 through February 2013 to fight off her breast cancer. More than three years later her hair still didn’t grow back, leaving her self-esteem scarred and causing her immense distress. According to Free’s claim, defendants concealed the existence of studies that proved the risk from the regulators, doctors, and patients. The woman holds the company liable for negligence and failure to warn, breach of warranty, fraudulent concealment and misrepresentation, fraud and deceit.